Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · IEX Real-Time Price · USD

7.35

-0.05 (-0.68%)

At close: Apr 19, 2024, 4:00 PM

7.22

-0.13 (-1.77%)

After-hours: Apr 19, 2024, 7:57 PM EDT

Recursion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	44.58	39.84	10.18	3.96	2.32
Revenue Growth (YoY)	11.88%	291.46%	156.89%	70.85%	-
Cost of Revenue	42.59	48.28	0	0	0
Gross Profit	1.99	-8.43	10.18	3.96	2.32
Selling, General & Admin	110.82	81.6	57.68	25.26	18.95
Research & Development	241.23	155.7	135.27	63.32	45.81
Operating Expenses	352.05	237.3	192.95	88.58	64.76
Operating Income	-350.06	-245.73	-182.78	-84.62	-62.44
Other Expense / Income	-17.93	-6.25	3.7	2.39	-0.56
Pretax Income	-332.13	-239.48	-186.48	-87.01	-61.88
Income Tax	-4.06	0	0	0	0
Net Income	-328.07	-239.48	-186.48	-87.01	-61.88
Shares Outstanding (Basic)	208	176	125	22	22
Shares Outstanding (Diluted)	208	176	125	22	22
Shares Change	18.41%	40.04%	475.48%	0.98%	-
EPS (Basic)	-1.58	-1.36	-1.49	-3.99	-2.87
EPS (Diluted)	-1.58	-1.36	-1.49	-3.99	-2.87
Free Cash Flow	-299.74	-120.58	-198.41	-51.23	-60.95
Free Cash Flow Per Share	-1.44	-0.69	-1.58	-2.35	-2.83
Gross Margin	4.46%	-21.16%	100.00%	100.00%	100.00%
Operating Margin	-785.33%	-616.74%	-1795.79%	-2135.66%	-2692.58%
Profit Margin	-735.99%	-601.05%	-1832.18%	-2196.01%	-2668.35%
Free Cash Flow Margin	-672.43%	-302.65%	-1949.42%	-1293.03%	-2628.37%
EBITDA	-299.66	-219.99	-178.07	-83.06	-59.39
EBITDA Margin	-672.27%	-552.14%	-1749.60%	-2096.49%	-2561.02%
Depreciation & Amortization	32.47	19.49	8.41	3.94	2.49
EBIT	-332.13	-239.48	-186.48	-87.01	-61.88
EBIT Margin	-745.10%	-601.05%	-1832.18%	-2196.01%	-2668.35%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).